Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal ...Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface.To this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD.The nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV functionalization.This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.展开更多
基金Belgian F.R.S.-FNRS(Fonds de la recherche scientifique)under grants WELBIO-CR-2022A-02The Excellence Of Science(EOS:program no.EOS 30770923 and 40007505)+4 种基金supported by the Marie Skłodowska-Curie Actions for an Individual European Fellowship under the European Union’s Horizon 2020 research and innovation program(grant agreement no.887609)by a FRS-FNRS fellowship(grant agreement no.40000747)(Belgium)partially supported by the FRS-FNRS(convention T.0013.19)FRFS-WELBIO,with the support of the Wallon region(under grant agreement WELBIO-CR-2022 S-01)has received funding from the European Research Council(ERC)under the European Union’s Horizon 2020 research and innovation program(grant agreement No.850997-NanoGut).
文摘Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface.To this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD.The nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV functionalization.This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.
